A History of the US Medical Cannabis Movement and Its Importance to Pediatricians: Science Versus Politics in Medicine’s Greatest Catch-22

Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4:1614-1648. doi:10.1002/cbdv.200790144

Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry. 2006;28:153-157. doi:10.1590/S1516-44462006000200015

Aggarwal SK Carter GT Sullivan MD ZumBrunnen C Morrill R Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5:153-168.

O’Shaughnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis Indica) their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov Med J Retrosp Med Sci. 1843;5:363-369.

Authority of the National Medical Convention. The Pharmacopeia of the United States of America. https://babel.hathitrust.org/cgi/pt?id=uc1.b4330104;view=1up;seq=7. Accessed November 26, 2018.

Reynolds JR . Therapeutic uses and toxic effects of Cannabis indica. Lancet. 1890;1:637-638.

Fankhauser M . History of cannabis in Western medicine. In: Grotenhermen F Russo E , eds. Cannabis and Cannabinoids. New York, NY: Haworth Integrative Healing Press; 2002:37-51.

Schlosser E . Reefer madness. The Atlantic. https://www.theatlantic.com/past/docs/politics/crime/reefm.htm. Published August 1994. Accessed November 21, 2018.

Siff S . The illegalization of marijuana: a brief history. Origins. http://origins.osu.edu/article/illegalization-marijuana-brief-history. Published May 2014. Accessed November 23, 2018.

National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017. doi:10.17226/24625

Marihuana Tax Act of 1937. 75th Congress, 1st Session-CHS. 552, 553-August 2, 1937. https://www.loc.gov/law/help/statutes-at-large/75th-congress/session-1/c75s1ch553.pdf. Published August 2, 1937. Accessed August 27, 2019.

Committee on Finance. US Senate, 75c 2s. HR6906. Library of Congress transcript. July 12, 1937.

Bonnie RJ Whitebread CH 2nd . The Marihuana Conviction: A History of Marihuana Prohibition in the United States. Charlottesville, VA: University Press of Virginia; 1974.

US Drug Enforcement Agency, Office of Diversion Control. Controlled substance schedules and list of controlled substances. https://www.deadiversion.usdoj.gov/schedules/. Accessed September 12, 2018.

Sharp EB. The Dilemma of Drug Policy in the United States. New York, NY: HarperCollins College; 1994.

US National Archives and Records Administration, Ronald Reagan Presidential Library & Museum. Radio address to the nation on Federal Drug Policy. https://www.reaganlibrary.gov/research/speeches/100282a. Published October 2, 1982. Accessed August 27, 2019.

Evans RI. Just say no campaign. In: Breslow L , ed. Encyclopedia of Public Health. New York, NY: Macmillan; 2002.

Fox M. Tod H. Mikuriya, 73, dies; backed medical marijuana. New York Times. https://www.nytimes.com/2007/05/29/health/29mikuriya.html?search-input=grandfather. Published May 29, 2007. Accessed September 12, 2018.

An issue honoring Tod Mikuriya, MD. O’Shaughnessy’s. Winter/Spring. 2008;46:10-16.

Mikuriya TH. Marijuana: Medical Papers, 1839-1972. Oakland, CA: Medi-Comp Press; 1973.

Mikuriya T. Chronic conditions treated with cannabis: reported to California doctors between 1990 and 2005. O’Shaughnessy’s. https://studyres.com/doc/5358108/data-suggest-possible-protective-effect. Published Autumn 2005. Accessed August 27, 2019.

Slonecker B . The counterculture of the 1960s and 1970s. http://americanhistory.oxfordre.com/view/10.1093/acrefore/9780199329175.001.0001/acrefore-9780199329175-e-392. Published June 2017. Accessed September 12, 2018.

Kandel DB. Marihuana users in young adulthood. Arch Gen Psychiatry. 1984;41:200-209.

Werner C. Marijuana, Gateway to Health: How Cannabis Protects Us From Cancer and Alzheimer’s Disease. San Francisco, CA: Dachstar Press; 2011.

Reuters. Dennis Peron, father of medical marijuana in California, dies at 72. https://www.reuters.com/article/us-people-dennisperon/dennis-peron-father-of-medical-marijuana-in-california-dies-at-72-idUSKBN1FH0XA. Published January 29, 2018. Accessed September 12, 2018.

California Legislative Information. State of California Health and Safety Code, ARTICLE 2. Cannabis [11357-11362.9] Section 11362.5. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?sectionNum=11362.5.&lawCode=HSC. Accessed January 26, 2019.

Society of Cannabis Clinicians. Mission. http://www.cannabisclinicians.org/about-scc-2/. Accessed September 12, 2018.

Hartig H Geiger AW . About six-in-ten Americans support marijuana legalization. https://www.pewresearch.org/fact-tank/2018/10/08/americans-support-marijuana-legalization/. Published October 8, 2018. Accessed May 25, 2019.

National Conference of State Legislatures. State medical marijuana laws. http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Published February 7, 2019. Accessed May 4, 2019.

Gaoni Y Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647. doi:10.1021/ja01062a046

Di Marzo V . A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci. 2006;27:134-140.

Hepler RS Frank IR. Marihuana smoking and intraocular pressure. JAMA. 1971;217:1392.

Mechoulam R Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65:174-179.

Cunha JM Carlini EA Pereira AE , et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175-185.

Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011;53(suppl 2):1-6. doi:10.1111/j.1469-8749.2011.03964.x

McIntosh AM McMahon J Dibbens LM , et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurol. 2010;9:592-598.

Porter BE Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574-577. doi:10.1016/j.yebeh.2013.08.037

Maa E Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55:783-786. doi:10.1111/epi.12610

GW Pharmaceuticals. History and approach. https://www.gwpharm.com/about/history. Accessed February 20, 2019

Devinsky O Cross JH Laux L , et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020. doi:10.1056/NEJMoa1611618

Thiele EA Marsh ED French JA , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085-1096. doi:10.1016/S0140-6736(18)30136-3

Devinsky O Patel AD Cross JH , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888-1897. doi:10.1056/NEJMoa1714631

Epidiolex (cannabidiol) [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf. Accessed January 29, 2019.

US Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm. Published June 25, 2018. Accessed September 12, 2018.

Marinol (dronabinol) [package insert]. North Chicago, IL: AbbVie Inc; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed January 29, 2019.

Syndros (dronabinol) [package insert]. Lakewood, NJ: Insys Therapeutics, Inc; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205525s007lbl.pdf. Accessed January 29, 2019.

Cesamet (nabilone) [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals International; 2006. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed January 29, 2019.

Sulak D Saneto R Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017;70(pt B):328-333. doi:10.1016/j.yebeh.2016.12.032

Aran A Cassuto H Lubotzky A Wattad N Hazan E. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. J Autism Dev Disord. 2019;49:1284-1288. doi:10.1007/s10803-018-3808-2

Bar-Lev Schleider L Mechoulam R Saban N Meiri G Novack V . Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9:200. doi:10.1038/s41598-018-37570-y

Takakuwa KM Hergenrather JY Goldstein B Sulak D . The Society of Cannabis Clinicians Grand Rounds #1: Cannabis in the Pediatric Population. May 4, 2018. https://www.cannabisclinicians.org/contact-us/

Wang GS. Pediatric concerns due to expanded cannabis use: unintended consequences of legalization. J Med Toxicol. 2017;13:99-105. doi:10.1007/s13181-016-0552-x

Jansson LM Jordan CJ Velez ML. Perinatal marijuana use and the developing child. JAMA. 2018;320:545-546. doi:10.1001/jama.2018.8401

Ryan SA Ammerman SD O’Connor ME ; Committee on Substance Use and Prevention; Section on Breastfeeding. Marijuana use during pregnancy and breastfeeding: implications for neonatal and childhood outcomes. Pediatrics. 2018;142:e20181889. doi:10.1542/peds.2018-1889

Hines L Glick J Bilka K Lantos JD. Medical marijuana for minors may be considered child abuse. Pediatrics. 2018;142:e20174310. doi:10.1542/peds.2017-4310